Journal
JOURNAL OF DIABETES AND ITS COMPLICATIONS
Volume 25, Issue 6, Pages 355-361Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jdiacomp.2011.10.003
Keywords
Type 2 diabetes; Intensive glucose control; Macrovascular risk and events
Categories
Funding
- Department of Veterans Affairs Office of Research and Development
- American Diabetes Association
- National Eye Institute of the NIH
- GlaxoSmithKline
- Novo Nordisk
- Roche Diagnostics
- Sanofi-Aventis
- Amylin
- Kos Pharmaceuticals
- Phoenix
Ask authors/readers for more resources
Background: The goal of the VA Diabetes Trial (VADT) was to determine the effect of intensive glucose control on macrovascular events in subjects with difficult-to-control diabetes. No significant benefit was found. This report examines predictors of the effect of intensive therapy on the primary outcome in this population. Methods: This trial included 1791 subjects. Baseline cardiovascular risk factors were collected by interview and the VA record. The analyses were done by intention to treat. Findings: Univariate analysis at baseline of predictors of a primary cardiovascular (CV) event included a prior CV event, age, insulin use at baseline, and duration of diagnosed diabetes (all P<.0001). Multivariable modeling revealed a U-shaped relationship between duration of diabetes and treatment. Modeled estimates for the hazard ratios (HRs) for treatment show that subjects with a short duration (3 years or less) of diagnosed diabetes have a nonsignificant increase in risk (HR > 1.0) after which the HR is below 1.0. From 7 to 15 years' duration at entry, subjects have HRs favoring intensive treatment. Thereafter the HR approaches 1.0 and over-21-years' duration approaches 2.0. Duration over 21 years resulted in a HR of 1.977 (CI 1.77-3.320, P<.01). Baseline c-peptide levels progressively declined up to 15 years and were stable subsequently. Interpretation: In difficult-to-control older subjects with type 2 DM, duration of diabetes altered the response to intensive glucose control. Intensive therapy may reduce CV events in subjects with a duration of 15 years or less and may increase risks in those with longer duration. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available